Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

NCT00234000 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped The study was closed due to poor enrollment

Conditions

Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: arsenic trioxide
DRUG: azacitidine

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]